“Coming off of a year of record growth, we began 2011 with a great sense of optimism...We could not be more pleased to see that the momentum of 2010 has continued."
Columbia, SC (Vocus/PRWEB) April 15, 2011
BDI Pharma, Inc. (BDI), the nation’s fastest growing national distributor of specialty biotherapeutics, announced that Sales Revenues for the first fiscal quarter of 2011 represented an increase of more than twenty-two percent (22%) compared with the same time period in 2010. Driving the company’s expansion was enhanced distribution within the Protein Biotherapeutics product line, specifically those pharmaceuticals offered in the company’s Hemophilia and Albumin (Human) portfolios. The therapeutic segments of Immunology and Oncology were also noted as significant contributors to BDI Pharma’s rising revenues.
“Coming off of a year of record growth, we began 2011 with a great sense of optimism, but also with expectations tempered by caution,” said Edward Stiefel, Jr., Co-President of BDI Pharma. “We could not be more pleased to see that the momentum of 2010 has continued.”
About BDI Pharma, Inc.
Since 1995, BDI Pharma has defined its customer-centric approach to serving the nation's healthcare community through innovative supply solutions, unparalleled customer service, extensive product knowledge, 24/7 emergency availability and urgent-need delivery. An open-access resource for reference material, educational literature, market data and online ordering, bdipharma.com (ivig.com) has become an industry-renowned point of reference. Proprietary programs for specialty veterinarians -- 4legpharma.com; product consignment -- consignadvantage.com; flu vaccine pre-booking and general vaccine ordering -- securivax.com; and purchasing/reward programs -- qoreprogram.com and securigam.com round out a family of solutions tailored to the needs of the healthcare community at large.
BDI Pharma’s portfolio includes branded and generic specialty pharmaceuticals, chemotherapy products, vaccines, albumin, IVIG, coagulation factors, high-titer or “hyper” immune globulins, and other specialty injectables. BDI Pharma is recognized as an “ADR,” or Authorized Distributor of Record, for all of the manufacturers it represents.